AMENDMENTS TO THE CLAIMS:

The following Listing of Claims replaces all prior versions, and listings, of claims.

LISTING OF CLAIMS

Claims 1-74 (Cancelled)

Claim [73] 75 (Currently Amended) A compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer.

Claim [74] 76 (Currently Amended) A compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer $-(CH_2)_lD[(CH_2)_nE]_m(CH_2)_pQ_q-$, wherein
l, m and n independently are 1-20 and p is 0-10,
Q is $-Z-(CH_2)_lD[(CH_2)_nG]_m(CH_2)_p-$,
q is an integer in the range from 0 to 5,
each D, E, and G independently are selected from -O-, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$, and $-P(OR^6)(O)-$, wherein R^3, R^4, R^5, and R^6 independently represent hydrogen or C_{1-6}-alkyl,
Z is selected from $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)NHCH_2CH_2-$, $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1
sor a pharmaceutically acceptable salt or prodrug thereof.

Claim [75] 77 (Currently Amended) A compound according to claim [74] 76, which has formula (I) :

A—W—B—Y—therapeutic polypeptide (I)

wherein
A is an albumin binding residue,
B is a hydrophilic spacer being $-(CH_2)_lD[(CH_2)_nE]_m(CH_2)_pQ_q-$, wherein
l, m and n independently are 1-20 and p is 0-10,
Q is $-Z-(CH_2)_lD[(CH_2)_nG]_m(CH_2)_p-$,
q is an integer in the range from 0 to 5,
each D, E, and G independently are selected from -O-, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$, and $-P(OR^6)(O)-$, wherein R^3, R^4, R^5, and R^6 independently represent hydrogen or C_{1-6}-alkyl,

Z is selected from -C(O)NH-, -C(O)NHCH$_2$-, -OC(O)NH -, -C(O)NHCH$_2$CH$_2$-, -C(O)CH$_2$-, -C(O)CH=CH-, -(CH$_2$)$_s$-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

W is a chemical group linking A and B.

Claim [76] 78 (Currently Amended) A compound according to claim [74] 76, which has formula (II)

A—W—B—Y—therapeutic polypeptide —Y′—B′-W′—A′ (II)

wherein

A and A′ are albumin binding residues,

B and B′ are hydrophilic spacers independently selected from -(CH$_2$)$_l$D [(CH$_2$)$_n$E]$_m$(CH$_2$)$_p$-Q$_q$-, wherein

l, m and n independently are 1-20 and p is 0-10,

Q is -Z-(CH$_2$)$_l$D[(CH$_2$)$_n$G]$_m$(CH$_2$)$_p$-,

q is an integer in the range from 0 to 5,

each D, E, and G independently are selected from -O-, -NR^3-, -N(COR^4)-, -PR^5(O)-, and -P(OR^6)(O)-, wherein R^3, R^4, R^5, and R^6 independently represent hydrogen or C$_{1-6}$-alkyl,

Z is selected from -C(O)NH-, -C(O)NHCH$_2$-, -OC(O)NH -, -C(O)NHCH$_2$CH$_2$-, -C(O)CH$_2$-, -C(O)CH=CH-, -(CH$_2$)$_s$-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

Y′ is a chemical group linking B′ and the therapeutic agent, and

W is a chemical group linking A and B, and

W′ is a chemical group linking A′ and B′.

Claim [77] 79 (Currently Amended) A compound according to claim [76] 78, wherein Y′ is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH$_2$-, -CH$_2$NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)NHCH$_2$-, CH$_2$NHC(O)-, -C(O)CH$_2$-, -CH$_2$C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH$_2$)$_s$-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and –C(O)NH-, wherein s is 0 or 1.

Claim [78] 80 (Currently Amended) A compound according to claim [76] 78, wherein W′ is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH$_2$-, -CH$_2$NHC(O)-, -OC(O)NH -, -

NHC(O)O-, -C(O)CH_2-, -CH_2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -$(CH_2)_s$-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and –C(O)NH-, wherein s is 0 or 1.

Claim [79] 81 (Currently Amended) A compound according to claim [74] 76, which has formula (III)



wherein

A and A′ are albumin binding residues,

B is a hydrophilic spacer selected from -$(CH_2)_l$D[$(CH_2)_n$E]$_m$$(CH_2)_p$-$Q_q$- wherein

l, m and n independently are 1-20 and p is 0-10,

Q is -Z-$(CH_2)_l$D[$(CH_2)_n$G]$_m$$(CH_2)_p$-,

q is an integer in the range from 0 to 5,

each D, E, and G are independently selected from -O-, -NR^3-, -N(COR^4)-, -PR^5(O)-, and -P(OR^6)(O)-, wherein R^3, R^4, R^5, and R^6 independently represent hydrogen or C_{1-6}-alkyl,

Z is selected from -C(O)NH-, -C(O)NHCH$_2$-, -OC(O)NH -, -C(O)NHCH$_2$CH$_2$-, -C(O)CH$_2$-, -C(O)CH=CH-, -$(CH_2)_s$-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

W′′ is a chemical group linking B with A and A′.

Claim [80] 82 (Currently Amended) A compound according to claim [79] 81, wherein W′′ is selected from the group consisting of



,

wherein s is 0, 1 or 2.

Claim [81] 83 (Currently Amended) A compound according to claim [75] 77, wherein Y is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH$_2$-, -CH$_2$NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)NHCH$_2$-, CH$_2$NHC(O)-, -C(O)CH$_2$-, -CH$_2$C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -$(CH_2)_s$-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and –C(O)NH-, wherein s is 0 or 1.

Claim [82] 84 (Currently Amended) A compound according to claim [75] 77, wherein W is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH$_2$-, -CH$_2$NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)CH$_2$-, -CH$_2$C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH$_2$)$_s$-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and –C(O)NH-, wherein s is 0 or 1.

Claim [83] 85 (Currently Amended) A compound according to claim [74] 76, wherein l is 1 or 2, n and m are independently 1-10 and p is 0-10.

Claim [84] 86 (Currently Amended) A compound according to claim [74] 76, wherein D is –O-.

Claim [85] 87 (Currently Amended) A compound according to claim [74] 76, wherein E is –O-.

Claim [86] 88 (Currently Amended) A compound according to claim [74] 76, wherein the hydrophilic spacer is
-CH$_2$O[(CH$_2$)$_2$O]$_m$(CH$_2$)$_p$Q$_q$-, where m is 1-10, p is 1-3, and Q is -Z-CH$_2$O[(CH$_2$)$_2$O]$_m$(CH$_2$)$_p$-.

Claim [87] 89 (Currently Amended) A compound according to claim [74] 76, wherein q is 0 or 1.

Claim [88] 90 (Currently Amended) A compound according to claim [74] 76, wherein q is 1.

Claim [89] 91 (Currently Amended) A compound according to claim [74] 76, wherein G is –O-.

Claim [90] 92 (Currently Amended) A compound according to claim [74] 76, wherein Z is selected from the group consisting of -C(O)NH-, -C(O)NHCH$_2$-, and –OC(O)NH-.

Claim [91] 93 (Currently Amended) A compound according to claim [74] 76, wherein q is 0.

Claim [92] 94 (Currently Amended) A compound according to claim [74] 76, wherein l is 2.

Claim [93] 95 (Currently Amended) A compound according to claim [74] 76, wherein n is 2.

Claim [94] 96 (Currently Amended)A compound according to claim [74] 76, wherein the hydrophilic spacer B is $-[CH_2CH_2O]_{m+1}(CH_2)_pQ_q-$.

Claim [95] 97 (Currently Amended) A compound according to claim [74] 76, wherein the hydrophilic spacer B is
$-(CH_2)_l-O-[(CH_2)_n-O]_m-(CH_2)_p-[C(O)NH-(CH_2)_l-O-[(CH_2)_n-O]_m-(CH_2)_p]_q-$,
where l, m, n, and p independently are 1-5, and q is 0-5.

Claim [96] 98 (Currently Amended) A compound according to claim [75] 77, wherein –W-B-Y- is selected from the group consisting of



,


,


,


,


,



,



, and



Claim [97] 99 (Currently Amended) A compound according to claim [79] 81, wherein >W´´-B-Y- is



Claim [98] 100 (Currently Amended) A compound according to claim [73] 75, wherein the molar weight of said hydrophilic spacer is in the range from 80D to 1000D or in the range from 80D to 300D.

Claim [99] 101 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is a lipophilic residue.

Claim [100] 102 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue binds non-covalently to albumin.

Claim [101] 103 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is negatively charged at physiological pH.

Claim [102] 104 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue has a binding affinity towards human serum albumin that is below about 10 μM.

Claim [103] 105 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an ω-carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton.

Claim [104] 106 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is a cibacronyl residue.

Claim [105] 107 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue has from 6 to 40 carbon atoms.

Claim [106] 108 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is a peptide.

Claim [107] 109 (Currently Amended) A compound according to claim [73] 75, wherein the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via the ε-amino group of a lysine residue.

Claim [108] 110 (Currently Amended) A compound according to claim [73] 75, wherein the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via a linker to an amino acid residue selected from cysteine, glutamate and aspartate.

Claim [109] 111 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is a glucagon-like peptide 1 (GLP-1) peptide.

Claim [110] 112 (Currently Amended) A compound according to claim [109] 111, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of the formula (IV):

Xaa_7-Xaa_8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa_{16}-Ser-Xaa_{18}-Xaa_{19}-Xaa_{20}-Glu-Xaa_{22}-Xaa_{23}-Ala-Xaa_{25}-Xaa_{26}-Xaa_{27}-Phe-Ile-Xaa_{30}-Trp-Leu-Xaa_{33}-Xaa_{34}-Xaa_{35}-Xaa_{36}-Xaa_{37}-Xaa_{38}-Xaa_{39}-Xaa_{40}-Xaa_{41}-Xaa_{42}-Xaa_{43}-Xaa_{44}-Xaa_{45}-Xaa_{46}

Formula (IV) (SEQ ID No: 2)

wherein

Xaa_7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N^{α}-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

Xaa_8 is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;

Xaa_{16} is Val or Leu;

Xaa_{18} is Ser, Lys or Arg;

Xaa_{19} is Tyr or Gln;

Xaa_{20} is Leu or Met;

Xaa_{22} is Gly, Glu or Aib;

Xaa_{23} is Gln, Glu, Lys or Arg;

Xaa_{25} is Ala or Val;

Xaa_{26} is Lys, Glu or Arg;

Xaa_{27} is Glu or Leu;

Xaa_{30} is Ala, Glu or Arg;

Xaa_{33} is Val or Lys;

Xaa_{34} is Lys, Glu, Asn or Arg;

Xaa_{35} is Gly or Aib;

Xaa_{36} is Arg, Gly or Lys;

Xaa_{37} is Gly, Ala, Glu, Pro, Lys, amide or is absent;

Xaa_{38} is Lys, Ser, amide or is absent.

Xaa_{39} is Ser, Lys, amide or is absent;

Xaa_{40} is Gly, amide or is absent;

Xaa_{41} is Ala, amide or is absent;

Xaa_{42} is Pro, amide or is absent;

Xaa_{43} is Pro, amide or is absent;

Xaa_{44} is Pro, amide or is absent;

Xaa_{45} is Ser, amide or is absent;

Xaa_{46} is amide or is absent ;

provided that if Xaa_{38}, Xaa_{39}, Xaa_{40}, Xaa_{41}, Xaa_{42}, Xaa_{43}, Xaa_{44}, Xaa_{45} or Xaa_{46} is absent then each amino acid residue downstream is also absent.

Claim [111] 113 (Currently Amended) A compound according to claim [110] 112, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V):

Xaa_7-Xaa_8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa_{18}-Tyr-Leu-Glu-Xaa_{22}-Xaa_{23}-Ala-Ala-Xaa_{26}-Glu-Phe-Ile-Xaa_{30}-Trp-Leu-Val-Xaa_{34}-Xaa_{35}-Xaa_{36}-Xaa_{37}-Xaa_{38}

Formula (V) (SEQ ID No: 3)

wherein

Xaa_7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N^{α}-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

Xaa_8 is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;

Xaa_{18} is Ser, Lys or Arg;

Xaa_{22} is Gly, Glu or Aib;

Xaa_{23} is Gln, Glu, Lys or Arg;

Xaa_{26} is Lys, Glu or Arg;

Xaa_{30} is Ala, Glu or Arg;

Xaa_{34} is Lys, Glu or Arg;

Xaa_{35} is Gly or Aib;

Xaa_{36} is Arg or Lys;

Xaa_{37} is Gly, Ala, Glu or Lys;

Xaa_{38} is Lys, amide or is absent.

Claim [112] 114 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is selected from GLP-1(7-35), GLP-1(7-36), GLP-1(7-36)-amide, GLP-1(7-37), GLP-1(7-38), GLP-1(7-39), GLP-1(7-40), GLP-1(7-41) or an analogue thereof.

Claim [113] 115 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide comprises no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

Claim [114] 116 (Currently Amended) A compound according to claim [113] 115, wherein said GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

Claim [115] 117 (Currently Amended) A compound according to claim [113] 115, wherein said GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code.

Claim [116] 118 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is a DPPIV protected GLP-1 peptide.

Claim [117] 119 (Currently Amended) A compound according to claim [109] 111, wherein said compound is DPPIV stabilised.

Claim [118] 120 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide comprises an Aib residue in position 8.

Claim [119] 121 (Currently Amended) A compound according to claim [109] 111, wherein the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N^{α}-acetyl-histidine , α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine.

Claim [120] 122 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is selected from the group consisting of Arg^{34}GLP-1(7-37), $Lys^{38}Arg^{26,34}$GLP-1(7-38), $Lys^{38}Arg^{26,34}$GLP-1(7-38)-OH, $Lys^{36}Arg^{26,34}$GLP-1(7-36), $Aib^{8,22,35}$ GLP-1(7-37), $Aib^{8,35}$ GLP-1(7-37), $Aib^{8,22}$ GLP-1(7-37), $Aib^{8,22,35}$ $Arg^{26,34}Lys^{38}$GLP-1(7-38), $Aib^{8,35}$ $Arg^{26,34}Lys^{38}$GLP-1(7-38), $Aib^{8,22}$ $Arg^{26,34}Lys^{38}$GLP-1(7-38), $Aib^{8,22,35}$ $Arg^{26,34}Lys^{38}$GLP-1(7-38), $Aib^{8,35}$ $Arg^{26,34}Lys^{38}$GLP-1(7-38), $Aib^{8,22,35}$ $Arg^{26}Lys^{38}$GLP-1(7-38), $Aib^{8,35}$ $Arg^{26}Lys^{38}$GLP-1(7-38), $Aib^{8,22}$ $Arg^{26}Lys^{38}$GLP-1(7-38), $Aib^{8,22,35}$ $Arg^{34}Lys^{38}$GLP-1(7-38), $Aib^{8,35}Arg^{34}Lys^{38}$GLP-1(7-38), $Aib^{8,22}Arg^{34}Lys^{38}$GLP-1(7-38), $Aib^{8,22,35}Ala^{37}Lys^{38}$GLP-1(7-38), $Aib^{8,35}Ala^{37}Lys^{38}$GLP-1(7-38), $Aib^{8,22}Ala^{37}Lys^{38}$GLP-1(7-38), $Aib^{8,22,35}$ Lys^{37}GLP-1(7-37), $Aib^{8,35}Lys^{37}$GLP-1(7-37) and $Aib^{8,22}Lys^{37}$GLP-1(7-38).

Claim [121] 123 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is attached to said hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence SEQ ID No:1.

Claim [122] 124 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is exendin-4.

Claim [123] 125 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-amide.

Claim [124] 126 (Currently Amended) A compound according to claim [109] 111, wherein one albumin binding residue via said hydrophilic spacer is attached to the C-terminal amino acid residue of said GLP-1 peptide.

Claim [125] 127 (Currently Amended) A compound according to claim [124] 126, wherein a second albumin binding residue is attached to an amino acid residue which is not the C-terminal amino acid residue.

Claim [126] 128 (Currently Amended) A compound according to claim [73] 75, wherein said compound is selected from the group consisting of

$N^{\varepsilon 37}$-(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}Lys^{37}$]GLP-1(7-37)amide



,

$N^{\varepsilon 37}$-(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}$,Lys^{37}] GLP-1 (7-37)amide



,

$N^{\varepsilon 37}$-{2-[2-(2-(15-carboxypentadecanoylamino)ethoxy)ethoxy]acetyl}-[$Aib^{8,22,35}$,Lys^{37}] GLP-1(7-37)amide



,

$N^{\varepsilon 37}$-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)[$Aib^{8,22,35}$,Lys^{37}]GLP-1(7-37)amide



,

$N^{\varepsilon 37}$-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[$Aib^{8,22,35}$,Lys^{37}]GLP-1(7-37)amide



,

[$Aib^{8,22,35}$,$Arg^{26,34}$]GLP-1-(7-37)Lys(4-(Hexadecanoylamino)-4(S)-carboxybutyryl)-OH



,

[$Aib^{8,22,35}$,$Arg^{26,34}$]GLP-1-(7-37)Lys(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-OH



,

$N^{\varepsilon 37}$(2-[2-(2,6-(S)-Bis-{2-[2-(2-(dodecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[$Aib^{8,22,35}$]GLP-1(7-37)amide



,

$N^{\varepsilon 37}$-(2-[2-(2,6-(S)-Bis-{2-[2-(2-(tetradecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[$Aib^{8,22,35}$]GLP-1(7-37)amide



,

[$Aib^{8,22,35}$,$Arg^{26,34}$]GLP-1-(7-37)Lys(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH



,

[Aib^{8,22,35}]GLP-1(7-37)Lys((2-{2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1-ylamino)-2-sulfo-phenylamino]-6-(2-sulfo-phenylamino)-[1,3,5]triazin-2-ylamino]-ethoxy}-ethoxy)-acetyl))amide



,

[Aib^{8,22,35}]GLP-1(7-37)Lys(({2-[2-(2-{2-[2-(2-{2-[2-(15-carboxypentadecanoylamino)-ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl))amide



,

N$^{\varepsilon 37}$-([2-(2-{3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]-propionylamino}ethoxy)ethoxy)acetyl]-[D-Ala^{8},Lys^{37}]-GLP-1-[7-

37]amide



,

[Aib^{8,22,35}Ala^{37}]GLP-1(7-37)Lys((2-(2-(2-(11-(oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl-)))amide



,

[Aib^{8,22,35},Ala^{37}]-GLP-1(7-37)Lys({2-[2-(2-{2-[2-(2-(15-carboxy-pentadecanoylamino)-ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl)amide



,

[Aib^{8,22,35},Ala^{37}]-GLP-1(7-37)Lys((2-{2-[11-(5-Dimethylaminonaphthalene-1-sulfonylamino)undecanoylamino]ethoxy}ethoxy)acetyl)amide



,

[Aib^{8,22,35},Ala^{37}]-GLP-1(7-37)Lys(([2-(2-{2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetylamino}ethoxy)ethoxy]acetyl))amide



,

[Aib^{8},Arg^{26,34},Glu^{22,23,30}]GLP-1 H(7-37)Lys(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl)amide



,

[Aib^{8},Arg^{26,34},Glu^{22,23,30}]GLP-1(7-37)Lys(2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl)amide



,

[Gly^{8},Arg^{26,34}] GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH



,

[Aib^{8},Arg^{26,34}]GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH



,

[Aib^{8}] -GLP-1-(7-37)Lys (2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH



,

[Aib^{8},Arg^{26,34}] GLP-1(7-37) Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH



,

[Aib^{8},Arg^{26,34}] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17-carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH



,

[Gly^{8}, Arg^{26,34}] GLP1-(7-37) Lys{2-(2-(2-(2-[2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH



,

[Aib^{8}]GLP-1-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetyl)-OH



$N^{\varepsilon 37}$-(2-(2-(2-(dodecanoylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}Lys^{37}$] GLP-1 H(7-37)-amide



$N^{\varepsilon 37}$-(2-(2-(2-(tetradecanoylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}Lys^{37}$] GLP-1 H(7-37)-amide



$N^{\varepsilon 37}$-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}Lys^{37}$] GLP-1 (7-37)-amide



$N^{\varepsilon 37}$-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}Lys^{37}$] GLP-1 (7-37)-amide



$N^{\varepsilon 37}$-(2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl)-[$Aib^{8,22,35}Lys^{37}$] GLP-1(7-37)-amide



$N^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))-[Aib^{8},$Arg^{26,34}$,Lys^{36}]GLP-1-(7-37)-OH



$N^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))[$Arg^{26,34}$,Lys^{36}]GLP-1(7-37)-OH



$N^{\varepsilon 36}$-{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-[Gly^{8},$Arg^{26,34}$,Lys^{36}]GLP-1-(7-37)-OH



,

$N^{\varepsilon 37}$-(2-(2-(2-(4-4(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononanoylsulfamoyl-butyrylamino)ethoxy)ethoxy)acetyl))[$Aib^{8,22,35}$,Lys^{37}] GLP-1-(7-37)-OH



,

$N^{\varepsilon 37}$-(2-(2-(2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,12-Heneicosafluoro-dodecyloxyacetylamino)ethoxy)
ethoxy)acetyl)[$Aib^{8,22,35}$,Lys^{37}]GLP-1-(7-37)-OH



,

$N^{\varepsilon 37}$-(2-(2-(2-(4-(hexadecanoylsulfamoyl)butyrylamino)ethoxy)ethoxy)acetyl)[$Aib^{8,22,35}$,Lys^{37}] GLP-1-(7-37)-OH



,

[Arg^{26,34}]GLP-1(7-37)Lys({2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH



,

[Arg^{26,34}] GLP-1(7-37)Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH



,

N$^{\varepsilon 20}${2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-exendin(1-39)



,

[Ala^{8}, Arg^{26,34}]GLP-1(7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro-benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide



,

[Aib^{8,22,35}]GLP-1(7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro-benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide



,

N$^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Aib^{8},Arg^{26,34},Lys^{36}]GLP-1-(7-37)-OH



,

$N^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Gly^{8},$Arg^{26,34}$,Lys^{36}]GLP-1-(7-37)-OH



,

$N^{\varepsilon 37}$-2-(2-(2-(4-(4-(Heptadecanoylamino)-4-(S)-carboxybutyrylamino)-4-(S)-carboxybutyrylamino)ethoxy)ethoxy) acetyl-[$Aib^{8,22,35}$,Lys^{37}]GLP-1-(7-37)-NH_2



,

$N^{\varepsilon 37}$-2-(2-[2-(2-[2-(4-[4-(Heptadecanoylamino)-4-(S) carboxybutyrylamino]-4-(S)-carboxybutyrylamino)ethoxy] ethoxy)acetylamino)ethoxy]ethoxy)acetyl-[$Aib^{8,22,35}$,Lys^{37}]GLP-1-(7-37)-NH_2



,

$N^{\varepsilon 26}$-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino) ethoxy)ethoxy)acetyl)-[Aib^{8},Arg^{34}]GLP-1-(7-37)- -OH



,

$N^{\varepsilon 26}$-2-(2-2-(2-(2-(2-(4-(Octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl-[Aib^{8}, Arg^{34}]GLP-1-(7-37)-OH



,

[Gly^{8},$Arg^{26,34}$]GLP-1(7-37)Lys(2-(2-(19-(carboxy)nonadecanoylamino)ethoxy)ethoxy)acetyl)-OH



,

[Gly^{8},Arg^{26,34}]GLP-1(7-37)Lys((2-(2-(17-(carboxy)heptadecanoylamino)ethoxy)ethoxy)acetyl))-OH



,

[Gly^{8},Arg^{26,34}]GLP-1(7-37)Lys(2-(2-(2-(4-(19-(carboxy)nonadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH



,

[Gly^{8},Arg^{26,34}]GLP-1(7-37)Lys((2-(2-(2-(2-(2-(2-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)-acetyl)-OH



,

[Gly^{8}, Arg^{26,34}]GLP-1 (7-37)Lys (2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)-acetylamino)ethoxy)ethoxy)acetyl) NH_2



,

$N^{\varepsilon 20}$(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(4-(17-(carboxy)heptadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Lys^{20}]exendin-4 (1-39)-NH_2



,

$N^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Aib^{8},$Arg^{26,34}$, Lys^{36}] GLP-1 (7-37)



,

N-$^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [$Arg^{26,34}$, Lys^{36}] GLP-1 (7-37)



,

$N^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Gly^{8},$Arg^{26,34}$,Lys^{36}] GLP-1 (7-37)



,

$N^{\varepsilon 20}$-(2-(2-(2-(2-(2-(2-(2-(2-(2-(Octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)-ethoxy)acetyl)[Lys^{20}] Exendin-4 (1-39)amide



,

$N^{\varepsilon 36}$-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[$Arg^{26,34}$,Lys^{36}]GLP-1-(7-37)



,

$N^{\varepsilon 26}$-(2-[2-(2-[2-(2-[2-(17-Carboxyheptadecanoylamino)ethoxy]ethoxy)acetylamino]ethoxy)ethoxy]acetyl)[Arg^{34}]GLP-1-(7-37)-OH



,

$N^{\varepsilon 26}$-[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg^{34}]GLP-1-(7-37)-OH



,

$N^{\varepsilon 20}$-(2-(2-(2-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl-amino)ethoxy)ethoxy)acetyl)[Lys^{20}] Exendin-4 (1-39) amide



,

[Gly^{8}, $Glu^{22,23,30}$, $Arg^{18,26,34}$]GLP1 (7-37) Lys(2-(2-(2-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy))ethoxy)acetyl)-NH_2



,

[Imidazolylpropionic acid^{7}, Asp^{16}, Aib^{22,35}]GLP1(7-37)Lys NH((2-{[4-(17-carboxyheptadecanoylamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))



,

[Imidazolylpropionic acid^{7}, Aib^{22,35}]GLP1(7-37)Lys NH((2-{[4-(17-carboxyheptadecanoylamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))



,

and

[3-(5-Imidazoyl)propionyl^{7}, Aib^{8}, Arg^{26,34}] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17-carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH



Claim [127] 129 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is a glucagon-like peptide 2 (GLP-2) peptide.

Claim [128] 130 (Currently Amended) A compound according to claim [127] 129, wherein said GLP-2 peptide is a DPPIV-protected GLP-2 peptide.

Claim [129] 131 (Currently Amended) A compound according to claim [127] 129, wherein said GLP-2 peptide is Gly^{2}-GLP-2(1-33).

Claim [130] 132 (Currently Amended) A compound according to claim [127] 129, wherein said GLP-2 peptide is $Lys^{17}Arg^{30}$-GLP-2(1-33).

Claim [131] 133 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is human insulin or an analogue thereof.

Claim [132] 134 (Currently Amended) A compound according to claim [131] 133, wherein said therapeutic polypeptide is selected from the group consisting of Asp^{B28}-human insulin, Lys^{B28},Pro^{B29}-human insulin, Lys^{B3},Glu^{B29}-human insulin, Gly^{A21},Arg^{B31},Arg^{B32}-human insulin and des(B30) human insulin.

Claim [133] 135 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is human growth hormone or an analogue thereof.

Claim [134] 136 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is parathyroid hormone or an analogue thereof.

Claim [135] 137 (Currently Amended) A compound according to claims [73] 75, wherein said therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof.

Claim [136] 138 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide has a molar weight of less than 100 kDa.

Claim [137] 139 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is selected from the group consisting of a growth factor, a somatomedin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1, plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, a colony stimulating factor (CFS), a stem cell factor, a tumor necrosis factor, a protease inhibitor, an opioid, a hormone, a neuropeptide, and a melanocortin.

Claim [138] 140 (Currently Amended) A pharmaceutical composition comprising a compound according to claim [73] 75 and a pharmaceutically acceptable excipient.

Claim [139] 141 (Currently Amended) The pharmaceutical composition according to claim [138] 140, which is suited for parenteral administration.

Claim [140] 142 (Currently Amended) A method for treating hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders, atheroschlerosis, myocardial infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory bowel syndrome, dyspepsia or gastric ulcers, said

method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim [109] 111.

Claim [141] 143 (Currently Amended) A method for delaying or preventing disease progression in type 2 diabetes in a subject, said method comprising administering to said subject an effective amount of a compound according to claim [109] 111.

Claim [142] 144 (Currently Amended) A method for decreasing food intake, decreasing β-cell apoptosis, increasing β-cell function and β-cell mass, and/or for restoring glucose sensitivity to β-cells in a subject, said method comprising administering to said subject an effective amount of a compound according to claim [109] 111.

Claim [143] 145 (Currently Amended) A method for treating small bowel syndrome, inflammatory bowel syndrome or Crohns disease, said method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim [127] 129.

Claim [144] 146 (Currently Amended) A method for treating hyperglycemia, type 1 diabetes, type 2 diabetes or β-cell deficiency, said method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim [131] 133.